Synonyms: compound 10 [US20160244432] | PI3Kdelta-IN-2 | YY-20394 | YY20394
Compound class:
Synthetic organic
Comment: Linperlisib (YY-20394) is a PI3Kδ inhibitor claimed by Shanghai Yingli Pharmaceutical Company in their patent US20160244432A1 (as compound 10) [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
YY-20394 has been advanced to early stage clinical evaluation in solid tumours and haematological cancers. Click here to link to ClinicalTrials.gov's full list of YY-20394 studies. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04049929 | A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors | Phase 1 Interventional | Shanghai YingLi Pharmaceutical Co. Ltd. | ||
NCT03757000 | A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies | Phase 1 Interventional | Shanghai YingLi Pharmaceutical Co. Ltd. | ||
NCT04108325 | A Phase Ib Study of YY-20394 in Patients With Recurrent or Refractory Peripheral T-Cell Lymphoma | Phase 1 Interventional | Shanghai YingLi Pharmaceutical Co. Ltd. |